31 results match your criteria dopps cardiac


Routinely measured cardiac troponin I and N-terminal pro-B-type natriuretic peptide as predictors of mortality in haemodialysis patients.

ESC Heart Fail 2022 Jan 13. Epub 2022 Jan 13.

Fukuoka Renal Clinic, Fukuoka, Japan.

Aims: Cardiac troponin (cTn) and B-type natriuretic peptide (BNP) are elevated in haemodialysis (HD) patients, and this elevation is associated with HD-induced myocardial stunning/myocardial strain. However, studies using data from the international Dialysis Outcomes and Practice Patterns Study (DOPPS) have shown that these cardiac biomarkers are measured in <2% of HD patients in real-world practice. This study aimed to examine whether routinely measured N-terminal pro-BNP (NT-proBNP) and cTnI (contemporary assay) are more appropriate than clinical models for reclassifying the risk of HD patients who have the highest risk of death. Read More

View Article and Full-Text PDF
January 2022

Thrombocytopenia predicts mortality in Chinese hemodialysis patients- an analysis of the China DOPPS.

BMC Nephrol 2022 Jan 3;23(1):11. Epub 2022 Jan 3.

Department of Nephrology, Peking University People's Hospital, Unit 10C in Ward Building; 11 Xizhimennan Street, Xicheng District, Beijing, 100044, China.

Background: Hemodialysis (HD) patients have a higher mortality rate compared with general population. Our previous study revealed that platelet counts might be a potential risk factor. The role of platelets in HD patients has rarely been studied. Read More

View Article and Full-Text PDF
January 2022

Facility Variation and Predictors of Do Not Resuscitate Orders of Hemodialysis Patients in Canada: DOPPS.

Can J Kidney Health Dis 2019 4;6:2054358119879777. Epub 2019 Oct 4.

The Ottawa Hospital, ON, Canada.

Background: Life expectancy in patients with end-stage kidney disease treated with hemodialysis (HD) is limited, and as such, the presence of an advanced care directive (ACD) may improve the quality of death as experienced for patients and families. Strategies to discuss and implement ACDs are limited with little being known about the status of Do Not Resuscitate (DNR) orders in the Canadian HD population.

Objectives: Using data from the Dialysis Outcomes and Practice Patterns Study (DOPPS), we set out to (1) examine the variability in DNR orders across Canada and its largest province, Ontario and (2) identify clinical and functional status measures associated with a DNR order. Read More

View Article and Full-Text PDF
October 2019

Cardiovascular Event Rates Among Hemodialysis Patients Across Geographical Regions-A Snapshot From The Dialysis Outcomes and Practice Patterns Study (DOPPS).

Kidney Int Rep 2019 Jun 28;4(6):864-872. Epub 2019 Mar 28.

Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA.

Introduction: Cardiovascular (CV) morbidity and mortality are excessively high among hemodialysis (HD) patients. Anemia is a common complication of chronic kidney disease (CKD) and a known risk factor for CV events. To understand the impact of the recent regulatory and guideline changes in anemia management, we examined regional CV event rates in high-risk and erythropoiesis-stimulating agent (ESA)-hyporesponsive HD patients. Read More

View Article and Full-Text PDF

Missed Hemodialysis Treatments: International Variation, Predictors, and Outcomes in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Am J Kidney Dis 2018 11 23;72(5):634-643. Epub 2018 Aug 23.

Arbor Research Collaborative for Health, Ann Arbor, MI. Electronic address:

Rationale & Objective: Missed hemodialysis (HD) treatments not due to hospitalization have been associated with poor clinical outcomes and related in part to treatment nonadherence. Using data from the Dialysis Outcomes and Practice Patterns Study (DOPPS) phase 5 (2012-2015), we report findings from an international investigation of missed treatments among patients prescribed thrice-weekly HD.

Study Design: Prospective observational study. Read More

View Article and Full-Text PDF
November 2018

DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients.

Kidney Int 2018 09 13;94(3):589-598. Epub 2018 Jun 13.

Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA; University of Michigan, Department of Internal Medicine, Ann Arbor, Michigan, USA.

The benefits of renin angiotensin-aldosterone system inhibitors (RAASi) are well-established in the general population, particularly among those with diabetes, congestive heart failure (CHF), or coronary artery disease (CAD). However, conflicting evidence from trials and concerns about hyperkalemia limit RAASi use in hemodialysis patients, relative to other antihypertensive agents, including beta blockers and calcium channel blockers. Therefore, we investigated prescription patterns and associations with mortality for RAASi and other antihypertensive agents using data from the international Dialysis Outcomes and Practice Patterns Study (DOPPS). Read More

View Article and Full-Text PDF
September 2018

Mortality risk in patients on hemodiafiltration versus hemodialysis: a 'real-world' comparison from the DOPPS.

Nephrol Dial Transplant 2018 04;33(4):683-689

Arbor Research Collaborative for Health, Ann Arbor, MI, USA.

Background: With its convective component, hemodiafiltration (HDF) provides better middle molecule clearance compared with hemodialysis (HD) and is postulated to improve survival. A previous analysis of Dialysis Outcomes and Practice Patterns Study (DOPPS) data in 1998-2001 found lower mortality rates for high replacement fluid volume HDF versus HD. Randomized controlled trials have not shown uniform survival advantage for HDF; in secondary (non-randomized) analyses, better outcomes were observed in patients receiving the highest convection volumes. Read More

View Article and Full-Text PDF

RAS Inhibitor Is Not Associated With Cardiovascular Benefits in Patients Undergoing Hemodialysis in Japan.

Ther Apher Dial 2017 Aug;21(4):326-333

Department of Epidemiology and Healthcare Research, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Definitive evidence of whether renin angiotensin system (RAS) inhibition is beneficial on cardiovascular events (CVE) among patients undergoing hemodialysis (HD) is lacking. The objective of this study was to investigate the association of RAS inhibitor usage with CVEs in patients enrolled in the Dialysis Outcomes Practice Pattern Study in Japan (J-DOPPS). Association of RAS inhibitor prescription with outcomes including all-cause death, death caused by CVE, and hospitalization due to cardiac failure was investigated by using a multivariable Cox proportional hazards model. Read More

View Article and Full-Text PDF

Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study.

BMC Nephrol 2017 Mar 20;18(1):97. Epub 2017 Mar 20.

Department of Nephrology, University hospital, Vandoeuvre les Nancy, France.

Background: Intravenous iron is widely used to control anemia in dialysis patients and limits costs related to erythropoiesis-stimulating agents (ESA). Current guidelines do not clearly set upper limits for serum ferritin (SF) and transferrin saturation (TSAT). International surveys such as the Dialysis Outcomes and Practice Patterns Study (DOPPS) showed that this lack of upper limits potentially led nephrologists to prescribe iron infusions even for patients with a high SF. Read More

View Article and Full-Text PDF

Cardiovascular and cerebrovascular comorbidities in hemodialysis patients from the Gulf Cooperation Council countries enrolled in the dialysis outcome and practice pattern study phase 5 (2012-2015).

Saudi J Kidney Dis Transpl 2016 11;27(6 Suppl 1):S24-30

List of Study Group in Acknowledgement.

To determine the prevalence of cardiovascular comorbidities and their active risk factors in the selected hemodialysis centers in the Gulf Cooperation Council (GCC) countries, the Dialysis Outcome and Practice Pattern Study (DOPPS) was performed on 40 dialysis centers in the six GCC countries from June 2012 to May 2015. There were 21 dialysis centers from Saudi Arabia, nine from the United Arab Emirates (UAE), four from Kuwait, four from Oman, two from Qatar, and one from Bahrain. There were 922 patients participating in the study; 419 patients from Saudi Arabia, 144 from the UAE, 164 from Kuwait, 89 from Oman, 58 from Qatar, and 25 from Bahrain. Read More

View Article and Full-Text PDF
November 2016

Dialysate Potassium, Serum Potassium, Mortality, and Arrhythmia Events in Hemodialysis: Results From the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Am J Kidney Dis 2017 Feb 17;69(2):266-277. Epub 2016 Nov 17.

Arbor Research Collaborative for Health, Ann Arbor, MI; Vanderbilt University, Nashville, TN.

Background: Sudden death is a leading cause of death in patients on maintenance hemodialysis therapy. During hemodialysis sessions, the gradient between serum and dialysate levels results in rapid electrolyte shifts, which may contribute to arrhythmias and sudden death. Controversies exist about the optimal electrolyte concentration in the dialysate; specifically, it is unclear whether patient outcomes differ among those treated with a dialysate potassium concentration of 3 mEq/L compared to 2 mEq/L. Read More

View Article and Full-Text PDF
February 2017

Intensive Hemodialysis and Treatment Complications and Tolerability.

Am J Kidney Dis 2016 Nov;68(5S1):S43-S50

Section of Nephrology, Department of Medicine, University of Manitoba, Winnipeg, Canada; Department of Community Health Sciences, University of Manitoba, Winnipeg, Canada; Seven Oaks General Hospital Renal Program, Winnipeg, Canada.

Hemodialysis (HD) treatment can be difficult to tolerate. Common complications are intradialytic hypotension (IDH) and long time to recovery after an HD session. IDH, as defined by nadir systolic blood pressure < 90mmHg and intradialytic decline > 30mmHg, occurs in almost 8% of HD sessions. Read More

View Article and Full-Text PDF
November 2016

Association between changes in quality of life and mortality in hemodialysis patients: results from the DOPPS.

Nephrol Dial Transplant 2017 03;32(3):521-527

Arbor Research Collaborative for Health, Ann Arbor, MI, USA.

Background: Cross-sectional health-related quality of life (HR-QOL) measures are associated with mortality in hemodialysis (HD) patients. The impact of changes in HR-QOL on outcomes remains unclear. We describe the association of prior changes in HR-QOL with subsequent mortality among HD patients. Read More

View Article and Full-Text PDF

Development and validation of cardiovascular risk scores for haemodialysis patients.

Int J Cardiol 2016 Aug 20;216:68-77. Epub 2016 Apr 20.

Nephrology, RWTH University of Aachen, Aachen, Germany.

Background: A simple clinical tool to predict cardiovascular disease risk does not exist for haemodialysis patients. The long-term coronary risk Framingham Heart Study Risk score (FRS), although used in this population, may be inadequate. Therefore, we developed separate risk-scores for cardiovascular mortality (CVM) and cardiovascular morbidity & mortality (CVMM) in a Fresenius Medical Care-based haemodialysis patient cohort (AROii). Read More

View Article and Full-Text PDF

Development and validation of a predictive mortality risk score from a European hemodialysis cohort.

Kidney Int 2015 May 4;87(5):996-1008. Epub 2015 Feb 4.

Nephrology and Hypertension, University of Erlangen-Nuremberg, Erlangen, Germany.

Although mortality risk scores for chronic hemodialysis (HD) patients should have an important role in clinical decision-making, those currently available have limited applicability, robustness, and generalizability. Here we applied a modified Framingham Heart Study approach to derive 1- and 2-year all-cause mortality risk scores using a 11,508 European incident HD patient database (AROii) recruited between 2007 and 2009. This scoring model was validated externally using similar-sized Dialysis Outcomes and Practice Patterns Survey (DOPPS) data. Read More

View Article and Full-Text PDF

Effects of sleepiness on survival in Japanese hemodialysis patients: J-DOPPS study.

Nephron Clin Pract 2014 8;128(3-4):333-40. Epub 2015 Jan 8.

Dialysis Unit, University Hospital of the Ryukyus, Okinawa, Japan.

Sleep disorder and poor sleep quality are common in chronic hemodialysis (HD) patients. They have been claimed as a cause of morbidity and mortality. The relationship between the degree of sleepiness and survival has not been studied. Read More

View Article and Full-Text PDF

Recovery time, quality of life, and mortality in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Am J Kidney Dis 2014 Jul 14;64(1):86-94. Epub 2014 Feb 14.

Arbor Research Collaborative for Health, Ann Arbor, MI; University of Michigan, Ann Arbor, MI.

Background: There is limited information about the clinical and prognostic significance of patient-reported recovery time.

Study Design: Prospective cohort study.

Setting & Participants: 6,040 patients in the DOPPS (Dialysis Outcomes and Practice Patterns Study). Read More

View Article and Full-Text PDF

Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy.

Kidney Int 2010 Jun 6;77(12):1098-106. Epub 2010 Jan 6.

Georg Haas Dialysezentrum, Giessen, Germany.

Using data from the international Dialysis Outcomes and Practice Patterns Study (DOPPS), we determined incidence, prevalence, and outcomes among hemodialysis patients with atrial fibrillation. Cox proportional hazards models, to identify associations with newly diagnosed atrial fibrillation and clinical outcomes, were stratified by country and study phase and adjusted for descriptive characteristics and comorbidities. Of 17,513 randomly sampled patients, 2188 had preexisting atrial fibrillation, with wide variation in prevalence across countries. Read More

View Article and Full-Text PDF

Beta-blocker prescription and outcomes in hemodialysis patients from the Japan Dialysis Outcomes and Practice Patterns Study.

Nephron Clin Pract 2009 12;113(3):c132-9. Epub 2009 Aug 12.

Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Background/aims: Given the clear benefits of mortality reduction observed for most beta-blockers in clinical trials, they are relatively underused in hemodialysis patients. Since the outcomes associated with the use of beta-blockers are not fully known, we investigated their effect on mortality among a cohort of hemodialysis patients.

Methods: Data were analyzed from the Dialysis Outcomes and Practice Patterns Study phase II for 2,286 randomly selected patients on hemodialysis in Japan. Read More

View Article and Full-Text PDF

[Vascular access in the elderly: AVF vs CVC. A comment].

G Ital Nefrol 2008 Nov-Dec;25(6):625-7

U.O. Nefrologia e Dialisi, IRCCS Multimedica Holding S.p.A., Via Milanese 300, Sesto San Giovanni, MI, Italy.

The aging population starting hemodialysis treatment raises the question as to which is the best vascular access in an older patient with multiple complications. The center effect is an important element in the choice of a vascular access, as shown by the DOPPS data and by a recent audit held in Lombardy. However, other data show an increase in the use of permanent CVCs in the last years and other factors must be taken into account in this clinical choice. Read More

View Article and Full-Text PDF
December 2009

Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Am J Kidney Dis 2007 Oct;50(4):602-11

Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.

Background: We investigated aspirin-prescribing patterns and potential benefits on cardiovascular morbidity and mortality in hemodialysis patients.

Study Design: Cohort study.

Setting & Participants: Data included 28,320 randomly selected hemodialysis patients from the Dialysis Outcomes and Practice Patterns Study I and II. Read More

View Article and Full-Text PDF
October 2007

Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Clin J Am Soc Nephrol 2007 Jan 29;2(1):89-99. Epub 2006 Nov 29.

Department of Global Epidemiology, Amgen, Inc., Thousand Oaks, California 91320, USA.

Mortality risk among hemodialysis (HD) patients may be highest soon after initiation of HD. A period of elevated mortality risk was identified among US incident HD patients, and which patient characteristics predict death during this period and throughout the first year was examined using data from the Dialysis Outcomes and Practice Patterns Study (DOPPS; 1996 through 2004). A retrospective cohort study design was used to identify mortality risk factors. Read More

View Article and Full-Text PDF
January 2007

Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS).

Am J Kidney Dis 2007 Mar;49(3):426-31

Arbor Research Collaborative for Health, formerly University Renal Research and Education Association, Ann Arbor, MI, USA.

Background: Information about residual renal function (RRF) and outcomes associated with practices of diuretic use in patients with end-stage renal disease is not available worldwide.

Methods: Diuretic use was investigated in 16,420 hemodialysis patients from the Dialysis Outcomes and Practice Patterns Study, a prospective observational study of hemodialysis patients selected from nationally representative facilities on 3 continents. Logistic regressions were used to investigate associations between diuretic use and patient characteristics. Read More

View Article and Full-Text PDF

Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Circulation 2006 Oct 23;114(18):1914-22. Epub 2006 Oct 23.

Division of Cardiovascular Medicine, 473 W 12th Ave, Ohio State University, Columbus, OH 43202, USA.

Background: Patients with end-stage renal disease are at high risk for cardiovascular morbidity and mortality. The aims of the present study were to describe the prevalence of peripheral arterial disease (PAD) and its effects on prognosis and health-related quality of life (HRQOL) in an international cohort of patients on hemodialysis.

Methods And Results: Data from the Dialysis Outcomes and Practice Patterns Study (DOPPS), a prospective, international, observational study of hemodialysis patients (n=29,873), were analyzed. Read More

View Article and Full-Text PDF
October 2006

Anemia management and treatment response in patients on hemodialysis: the MAR study.

J Nephrol 2006 May-Jun;19(3):352-60

Nephrology Service, Alcorcón Hospital Foundation, Madrid, Spain.

Background: Anemia management guidelines describe the importance of anemia as a risk factor in hemodialysis and the need for clinical prospective studies focused on this role of anemia. Response to treatment with iron and epoetin is multifactorial, and results are still far from the targets set by the guidelines. The Morbidity and Mortality Anemia Renal study (MAR) is a multicenter prospective cohort study of hemodialysis (HD), designed to assess the burden of anemia on morbidity and mortality. Read More

View Article and Full-Text PDF
September 2006

Do central venous catheters have advantages over arteriovenous fistulas or grafts?

J Nephrol 2006 May-Jun;19(3):265-79

Department of Nephrology and Dialysis, S. Giovanni Bosco Hospital, Turin, Italy.

Central venous accesses have become an integral component of vascular access procedures for hemodialysis. Although the DOQI guidelines recommend that less than 10% of chronic hemodialysis patients should be maintained on catheters, in some countries higher prevalences are reported, as in the United States and the United Kingdom (18% and 24%, respectively, according to the DOPPS). The native arteriovenous fistulas are still the best suited accesses for hemodialysis. Read More

View Article and Full-Text PDF
September 2006

Large variations in prescriptions of gastrointestinal medications in hemodialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Hemodial Int 2006 Apr;10(2):180-8

Albany College of Pharmacy, Albany, New York 12208, USA.

Little is known about proton pump inhibitor (PPI) or H(2) receptor antagonist (HA) prescription patterns or regarding use of predictors in hemodialysis patients. Proton pump inhibitor and HA prescribing patterns were investigated in 8628 hemodialysis patients from seven countries enrolled in the prospective, observational Dialysis Outcomes and Practice Patterns Study. Logistic regression examined predictors associated with PPI and HA use, adjusting for age, sex, country, time with end-stage renal disease, medications, 14 comorbid conditions, and the association between the number of comorbid conditions and the prescription of gastrointestinal (GI) medications. Read More

View Article and Full-Text PDF

Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients.

Am J Kidney Dis 2004 Nov;44(5 Suppl 2):61-7

Universita Federico II, Naples, Italy.

Background: Medications affect many measures of hemodialysis patients' well-being.

Methods: The Dialysis Outcomes and Practice Patterns Study (DOPPS) has evaluated the use of hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins), analgesics, antidepressants, and multivitamins. Additionally, DOPPS has reported on the associations between vascular access outcomes and related medications. Read More

View Article and Full-Text PDF
November 2004

Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects.

Am J Kidney Dis 2004 Nov;44(5 Suppl 2):16-21

University Renal Research and Education Association, Ann Arbor, MI 48103, USA.

Background: The Dialysis Outcomes and Practice Patterns Study is well suited to identify case-mix effects, given its extensive data set. The data set was used to examine the influence of case-mix variables on mortality and the extent to which these variables account for differences in mortality across regions, as well as the prevalence and incidence of hepatitis B and hepatitis C.

Methods: Demographic and comorbid disease features were determined for 8,615 patients internationally; mortality was recorded for this cohort, plus replacement patients (total n = 16,720), from 1996 to 2002. Read More

View Article and Full-Text PDF
November 2004

Analgesic prescription patterns among hemodialysis patients in the DOPPS: potential for underprescription.

Kidney Int 2004 Jun;65(6):2419-25

Albany College of Pharmacy, Albany, New York 12208, USA.

Background: Dialysis patients require special consideration regarding analgesics, given their altered pharmacokinetic and pharmacodynamic profiles and increased potential for adverse reactions.

Methods: Analgesic prescription patterns were investigated using data from the Dialysis Outcomes and Practice Patterns Study (DOPPS), with 3749 patients in 142 United States facilities studied between May 1996 and September 2001.

Results: The proportion of patients prescribed any analgesic decreased from 30. Read More

View Article and Full-Text PDF